ASCO 2022 | AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer

Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, discusses findings from the phase III AMEERA-6 trial (NCT05128773) of amcenestrant, a selective estrogen receptor degrader (SERD), in patients with HR-positive early breast cancer who have discontinued aromatase inhibitors due to toxicity. Patients either received amcenestrant or tamoxifen, the current standard of care and whilst previous studies have demonstrated initial safety and efficacy in patients, the AMEERA-6 trial will assess durable responses following a 5-year follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.